Clinical Trial

Obesity and Endogenous Oxalate Synthesis

Study Description

Obesity and Endogenous Oxalate Synthesis

The goal of this proposal is to determine the contribution and significance of obesity to urinary oxalate excretion and thus calcium oxalate kidney stone disease. Successful completion of the study will provide insight into the link between obesity and kidney stone disease and should identify future strategies to treat this disease.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Normal Individuals

Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver

Calcium Oxalate Kidney Stone Formers

Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver

Type 2 Diabetes

Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver

Type 2 diabetic kidney stone formers

Stage I: Controlled Dietary Study Phase II: Glycolate Phase III: Vitamin C Participants that agree,will undergo MRI to evaluate fatty liver

Additional Information

Official Study Title

Obesity and Endogenous Oxalate Synthesis

Clinical Trial ID

NCT03808090

ParticipAid ID

bW6pXa